{
    "data": [
        {
            "id": "4133453",
            "type": "article",
            "attributes": {
                "publishOn": "2017-12-22T10:25:59-05:00",
                "isLockedPro": false,
                "commentCount": 123,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "My 4% Dividend Yield Portfolio: Q4 2017 Summary And Short-Term Expectations",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "73225",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4133453-4-percent-dividend-yield-portfolio-q4-2017-summary-and-short-term-expectations"
            }
        },
        {
            "id": "4133431",
            "type": "article",
            "attributes": {
                "publishOn": "2017-12-22T07:17:14-05:00",
                "isLockedPro": false,
                "commentCount": 16,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Attractively Valued Dividend Kings",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "21544",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4133431-attractively-valued-dividend-kings"
            }
        },
        {
            "id": "4130654",
            "type": "article",
            "attributes": {
                "publishOn": "2017-12-08T11:50:13-05:00",
                "isLockedPro": false,
                "commentCount": 14,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Esketamine Could Give Johnson & Johnson The Next Major Psych Blockbuster",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "64963",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "195527",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4130654-esketamine-give-johnson-and-johnson-next-major-psych-blockbuster"
            }
        },
        {
            "id": "4130553",
            "type": "article",
            "attributes": {
                "publishOn": "2017-12-07T21:55:17-05:00",
                "isLockedPro": false,
                "commentCount": 43,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Reliable Dividend Clipper",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24992",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4130553-johnson-and-johnson-reliable-dividend-clipper"
            }
        },
        {
            "id": "4128484",
            "type": "article",
            "attributes": {
                "publishOn": "2017-11-29T13:57:10-05:00",
                "isLockedPro": false,
                "commentCount": 13,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Buy The Pause",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102683",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4128484-johnson-and-johnson-buy-pause"
            }
        },
        {
            "id": "4128183",
            "type": "article",
            "attributes": {
                "publishOn": "2017-11-28T14:59:00-05:00",
                "isLockedPro": false,
                "commentCount": 219,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "3 Dividend-Paying Blue Chips That Could Leave Retirees Blue",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "88946",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4128183-3-dividend-paying-blue-chips-leave-retirees-blue"
            }
        },
        {
            "id": "4126807",
            "type": "article",
            "attributes": {
                "publishOn": "2017-11-21T11:05:30-05:00",
                "isLockedPro": false,
                "commentCount": 13,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Dividend King With Good Total Return And Dividend Growth",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "85096",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4126807-johnson-and-johnson-dividend-king-good-total-return-and-dividend-growth"
            }
        },
        {
            "id": "4125930",
            "type": "article",
            "attributes": {
                "publishOn": "2017-11-17T11:49:35-05:00",
                "isLockedPro": false,
                "commentCount": 30,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "The Right Time To Buy Johnson & Johnson",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103458",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4125930-right-time-to-buy-johnson-and-johnson"
            }
        },
        {
            "id": "4124670",
            "type": "article",
            "attributes": {
                "publishOn": "2017-11-14T12:53:41-05:00",
                "isLockedPro": false,
                "commentCount": 22,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Does This Dividend Giant Still Offer Value?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103599",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4124670-johnson-and-johnson-this-dividend-giant-still-offer-value"
            }
        },
        {
            "id": "4121202",
            "type": "article",
            "attributes": {
                "publishOn": "2017-11-06T13:41:38-05:00",
                "isLockedPro": false,
                "commentCount": 8,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson Pipeline Impresses",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "99576",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "194325",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4121202-johnson-and-johnson-pipeline-impresses"
            }
        },
        {
            "id": "4120115",
            "type": "article",
            "attributes": {
                "publishOn": "2017-11-03T11:44:34-04:00",
                "isLockedPro": false,
                "commentCount": 64,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "What To Hold If You're Afraid Of An Upcoming Bear Market",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "38631",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4120115-what-to-hold-afraid-of-upcoming-bear-market"
            }
        },
        {
            "id": "4119578",
            "type": "article",
            "attributes": {
                "publishOn": "2017-11-02T12:00:24-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Not Overvalued Per FCF Standpoint",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "65113",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "194232",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4119578-johnson-and-johnson-not-overvalued-per-fcf-standpoint"
            }
        },
        {
            "id": "4118691",
            "type": "article",
            "attributes": {
                "publishOn": "2017-10-31T14:24:43-04:00",
                "isLockedPro": false,
                "commentCount": 10,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Dividend Aristocrats In Focus Part 27: Johnson & Johnson",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "63883",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4118691-dividend-aristocrats-in-focus-part-27-johnson-and-johnson"
            }
        },
        {
            "id": "4118250",
            "type": "article",
            "attributes": {
                "publishOn": "2017-10-30T16:15:17-04:00",
                "isLockedPro": false,
                "commentCount": 27,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "FDA Approval And Impact Of Bayer's/Johnson & Johnson's Xarelto On Portola's Bevyxxa Sales",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103685",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4118250-fda-approval-and-impact-of-bayers-johnson-and-johnsons-xarelto-on-portolas-bevyxxa-sales"
            }
        },
        {
            "id": "4116060",
            "type": "article",
            "attributes": {
                "publishOn": "2017-10-24T22:04:58-04:00",
                "isLockedPro": false,
                "commentCount": 15,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "After The Earnings, I Prefer Johnson & Johnson, But Procter & Gamble Is A Better Deal",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "21151",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4116060-after-earnings-i-prefer-johnson-and-johnson-procter-and-gamble-is-better-deal"
            }
        },
        {
            "id": "4115472",
            "type": "article",
            "attributes": {
                "publishOn": "2017-10-23T12:13:13-04:00",
                "isLockedPro": false,
                "commentCount": 18,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Was It A Good Time To Buy Johnson & Johnson? Is It Now?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23468",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4115472-was-good-time-to-buy-johnson-and-johnson-is-now"
            }
        },
        {
            "id": "4115063",
            "type": "article",
            "attributes": {
                "publishOn": "2017-10-20T11:42:05-04:00",
                "isLockedPro": false,
                "commentCount": 14,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Your Daily Pharma Scoop: Johnson & Johnson's Mixed Signals, Celgene's Mongersen Failure, QURE's Hemophilia B Trial",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103050",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4115063-your-daily-pharma-scoop-johnson-and-johnsons-mixed-signals-celgenes-mongersen-failure-qures"
            }
        },
        {
            "id": "4115033",
            "type": "article",
            "attributes": {
                "publishOn": "2017-10-20T10:44:17-04:00",
                "isLockedPro": false,
                "commentCount": 12,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Create Your Own Dividends",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "21798",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4115033-johnson-and-johnson-create-your-own-dividends"
            }
        },
        {
            "id": "4114951",
            "type": "article",
            "attributes": {
                "publishOn": "2017-10-20T03:17:57-04:00",
                "isLockedPro": false,
                "commentCount": 26,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson Does It Again",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "39011",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4114951-johnson-and-johnson-again"
            }
        },
        {
            "id": "4114798",
            "type": "article",
            "attributes": {
                "publishOn": "2017-10-19T15:53:44-04:00",
                "isLockedPro": false,
                "commentCount": 122,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Is It Time To Take Profits On Johnson & Johnson?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "44781",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4114798-is-time-to-take-profits-on-johnson-and-johnson"
            }
        },
        {
            "id": "4114521",
            "type": "article",
            "attributes": {
                "publishOn": "2017-10-19T00:18:33-04:00",
                "isLockedPro": false,
                "commentCount": 94,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "J&J: Unattractive",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "43041",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4114521-j-and-j-unattractive"
            }
        },
        {
            "id": "4114383",
            "type": "article",
            "attributes": {
                "publishOn": "2017-10-18T14:22:04-04:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Fully Priced As Operating Momentum Accelerates",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25120",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "193697",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4114383-johnson-and-johnson-fully-priced-operating-momentum-accelerates"
            }
        },
        {
            "id": "4114247",
            "type": "article",
            "attributes": {
                "publishOn": "2017-10-18T10:24:59-04:00",
                "isLockedPro": false,
                "commentCount": 29,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson At All-Time Highs: Time To Sell Or To Buy?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "68315",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4114247-johnson-and-johnson-all-time-highs-time-to-sell-to-buy"
            }
        },
        {
            "id": "4114223",
            "type": "article",
            "attributes": {
                "publishOn": "2017-10-18T08:48:24-04:00",
                "isLockedPro": false,
                "commentCount": 11,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: One-Time Bumps",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "22148",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4114223-johnson-and-johnson-one-time-bumps"
            }
        },
        {
            "id": "4114209",
            "type": "article",
            "attributes": {
                "publishOn": "2017-10-18T08:22:54-04:00",
                "isLockedPro": false,
                "commentCount": 13,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Q3 Beat Was Low Quality",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102620",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4114209-johnson-and-johnson-q3-beat-was-low-quality"
            }
        },
        {
            "id": "4114203",
            "type": "article",
            "attributes": {
                "publishOn": "2017-10-18T07:25:02-04:00",
                "isLockedPro": false,
                "commentCount": 17,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: The Unsinkable",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "94046",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4114203-johnson-and-johnson-unsinkable"
            }
        },
        {
            "id": "4114147",
            "type": "article",
            "attributes": {
                "publishOn": "2017-10-17T23:17:05-04:00",
                "isLockedPro": false,
                "commentCount": 24,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Amazing Company, But There Is Something Wrong",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "21151",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4114147-johnson-and-johnson-amazing-company-is-something-wrong"
            }
        },
        {
            "id": "4114021",
            "type": "article",
            "attributes": {
                "publishOn": "2017-10-17T12:52:29-04:00",
                "isLockedPro": false,
                "commentCount": 17,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Understanding Johnson & Johnson's Spectacular Q3 Performance",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "63883",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4114021-understanding-johnson-and-johnsons-spectacular-q3-performance"
            }
        },
        {
            "id": "4113835",
            "type": "article",
            "attributes": {
                "publishOn": "2017-10-16T17:23:55-04:00",
                "isLockedPro": false,
                "commentCount": 52,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Take Profits On Johnson & Johnson",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102620",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4113835-take-profits-on-johnson-and-johnson"
            }
        },
        {
            "id": "4113117",
            "type": "article",
            "attributes": {
                "publishOn": "2017-10-12T10:30:32-04:00",
                "isLockedPro": false,
                "commentCount": 33,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "2 More Stocks That Warrant Consideration, Even This Close To Their 52-Week Highs",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "98446",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4113117-2-stocks-warrant-consideration-even-this-close-to-52-week-highs"
            }
        },
        {
            "id": "4113076",
            "type": "article",
            "attributes": {
                "publishOn": "2017-10-12T08:00:44-04:00",
                "isLockedPro": false,
                "commentCount": 9,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson Needs To Do This With The Consumer Segment",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "80476",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "193462",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4113076-johnson-and-johnson-needs-to-this-consumer-segment"
            }
        },
        {
            "id": "4112674",
            "type": "article",
            "attributes": {
                "publishOn": "2017-10-10T11:21:18-04:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Earnings Preview",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "39011",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4112674-johnson-and-johnson-earnings-preview"
            }
        },
        {
            "id": "4112202",
            "type": "article",
            "attributes": {
                "publishOn": "2017-10-06T20:08:24-04:00",
                "isLockedPro": false,
                "commentCount": 73,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Medtronic Is Not A Replacement For Johnson & Johnson",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102327",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4112202-medtronic-is-not-replacement-for-johnson-and-johnson"
            }
        },
        {
            "id": "4111975",
            "type": "article",
            "attributes": {
                "publishOn": "2017-10-05T16:38:38-04:00",
                "isLockedPro": false,
                "commentCount": 30,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Why I Would Still Pick Johnson & Johnson Over Medtronic",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "65113",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "193259",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4111975-why-i-still-pick-johnson-and-johnson-over-medtronic"
            }
        },
        {
            "id": "4111935",
            "type": "article",
            "attributes": {
                "publishOn": "2017-10-05T14:03:19-04:00",
                "isLockedPro": false,
                "commentCount": 43,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Which Dividend King Rules Them All - Johnson & Johnson Or Procter & Gamble?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "63883",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4111935-which-dividend-king-rules-all-johnson-and-johnson-procter-and-gamble"
            }
        },
        {
            "id": "4111640",
            "type": "article",
            "attributes": {
                "publishOn": "2017-10-04T13:33:06-04:00",
                "isLockedPro": false,
                "commentCount": 183,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "3 Reasons To Avoid This Legendary Dividend King In Favor Of A Far Superior Alternative",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101900",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4111640-3-reasons-to-avoid-this-legendary-dividend-king-in-favor-of-far-superior-alternative"
            }
        },
        {
            "id": "4111600",
            "type": "article",
            "attributes": {
                "publishOn": "2017-10-04T11:04:04-04:00",
                "isLockedPro": false,
                "commentCount": 20,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson And The Bull Case",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "39011",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "193192",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4111600-johnson-and-johnson-and-bull-case"
            }
        },
        {
            "id": "4111471",
            "type": "article",
            "attributes": {
                "publishOn": "2017-10-03T16:57:21-04:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Consumer Goods Firmly On The Growth Path?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103373",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "193178",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4111471-johnson-and-johnson-consumer-goods-firmly-on-growth-path"
            }
        },
        {
            "id": "4111437",
            "type": "article",
            "attributes": {
                "publishOn": "2017-10-03T15:32:16-04:00",
                "isLockedPro": false,
                "commentCount": 25,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Best of Breed in Healthcare",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103662",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4111437-johnson-and-johnson-best-of-breed-in-healthcare"
            }
        },
        {
            "id": "4109227",
            "type": "article",
            "attributes": {
                "publishOn": "2017-09-25T12:16:04-04:00",
                "isLockedPro": false,
                "commentCount": 40,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson Vs. Pfizer: Which Is A Better Buy?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103321",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4109227-johnson-and-johnson-vs-pfizer-which-is-better-buy"
            }
        },
        {
            "id": "4109181",
            "type": "article",
            "attributes": {
                "publishOn": "2017-09-25T10:38:47-04:00",
                "isLockedPro": false,
                "commentCount": 30,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson Is Not A Good Buy",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "80476",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4109181-johnson-and-johnson-is-not-good-buy"
            }
        },
        {
            "id": "4109061",
            "type": "article",
            "attributes": {
                "publishOn": "2017-09-24T22:22:32-04:00",
                "isLockedPro": false,
                "commentCount": 42,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "J&J: Thoughts On Sirukumab And Other Problems",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "43041",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4109061-j-and-j-thoughts-on-sirukumab-and-problems"
            }
        },
        {
            "id": "4108742",
            "type": "article",
            "attributes": {
                "publishOn": "2017-09-22T05:00:11-04:00",
                "isLockedPro": false,
                "commentCount": 7,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson Acquires Sightbox For Contact Lens Subscriptions",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101421",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4108742-johnson-and-johnson-acquires-sightbox-for-contact-lens-subscriptions"
            }
        },
        {
            "id": "4108054",
            "type": "article",
            "attributes": {
                "publishOn": "2017-09-19T14:24:26-04:00",
                "isLockedPro": false,
                "commentCount": 21,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson's Dividend Will Continue To Chug Along, But Likely At A Slower Pace",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "42381",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4108054-johnson-and-johnsons-dividend-will-continue-to-chug-along-likely-slower-pace"
            }
        },
        {
            "id": "4107387",
            "type": "article",
            "attributes": {
                "publishOn": "2017-09-15T17:29:59-04:00",
                "isLockedPro": false,
                "commentCount": 65,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson - This Is A Dividend Machine",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102551",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4107387-johnson-and-johnson-this-is-dividend-machine"
            }
        },
        {
            "id": "4105727",
            "type": "article",
            "attributes": {
                "publishOn": "2017-09-11T11:07:27-04:00",
                "isLockedPro": false,
                "commentCount": 6,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: How To Decrease Your Investment Returns",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "80476",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "192282",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4105727-johnson-and-johnson-how-to-decrease-your-investment-returns"
            }
        },
        {
            "id": "4105710",
            "type": "article",
            "attributes": {
                "publishOn": "2017-09-11T09:47:04-04:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson Finally Getting A Little Help",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "39011",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "192280",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4105710-johnson-and-johnson-finally-getting-little-help"
            }
        },
        {
            "id": "4105538",
            "type": "article",
            "attributes": {
                "publishOn": "2017-09-09T12:20:09-04:00",
                "isLockedPro": false,
                "commentCount": 11,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: (Some) More Room To Go",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "45851",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4105538-johnson-and-johnson-room-to-go"
            }
        },
        {
            "id": "4105212",
            "type": "article",
            "attributes": {
                "publishOn": "2017-09-08T07:18:19-04:00",
                "isLockedPro": false,
                "commentCount": 16,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson's New Focus",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103602",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "192211",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4105212-johnson-and-johnsons-new-focus"
            }
        },
        {
            "id": "4105097",
            "type": "article",
            "attributes": {
                "publishOn": "2017-09-07T16:27:23-04:00",
                "isLockedPro": false,
                "commentCount": 7,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Buy Johnson & Johnson Before Q3 Earnings",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102428",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "192200",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4105097-buy-johnson-and-johnson-q3-earnings"
            }
        },
        {
            "id": "4104803",
            "type": "article",
            "attributes": {
                "publishOn": "2017-09-07T11:21:37-04:00",
                "isLockedPro": false,
                "commentCount": 15,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "This Is How Johnson & Johnson Is Funding Your Dividend Increases",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "39011",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4104803-this-is-how-johnson-and-johnson-is-funding-your-dividend-increases"
            }
        },
        {
            "id": "4104762",
            "type": "article",
            "attributes": {
                "publishOn": "2017-09-07T09:16:23-04:00",
                "isLockedPro": false,
                "commentCount": 25,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "The Deck Is Stacked Against Johnson & Johnson",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102757",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4104762-deck-is-stacked-against-johnson-and-johnson"
            }
        },
        {
            "id": "4103930",
            "type": "article",
            "attributes": {
                "publishOn": "2017-09-04T08:10:08-04:00",
                "isLockedPro": false,
                "commentCount": 69,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: How Does An $11 Special Dividend Sound To You?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "80476",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4103930-johnson-and-johnson-how-11-special-dividend-sound-to-you"
            }
        },
        {
            "id": "4102607",
            "type": "article",
            "attributes": {
                "publishOn": "2017-08-29T09:04:19-04:00",
                "isLockedPro": false,
                "commentCount": 11,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson's Darzalex Is An Emerging Threat To The Primacy Of Celgene's Revlimid",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "56012",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4102607-johnson-and-johnsons-darzalex-is-emerging-threat-to-primacy-of-celgenes-revlimid"
            }
        },
        {
            "id": "4102373",
            "type": "article",
            "attributes": {
                "publishOn": "2017-08-28T13:10:08-04:00",
                "isLockedPro": false,
                "commentCount": 16,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "J&J Investors Should Ignore The Noise Of Cancer Lawsuits For Now",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101693",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4102373-j-and-j-investors-should-ignore-noise-of-cancer-lawsuits-for-now"
            }
        },
        {
            "id": "4101855",
            "type": "article",
            "attributes": {
                "publishOn": "2017-08-25T07:16:55-04:00",
                "isLockedPro": false,
                "commentCount": 89,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "California Jury Drops A $417 Million Talc Bomb On J&J",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "31441",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4101855-california-jury-drops-417-million-talc-bomb-on-j-and-j"
            }
        },
        {
            "id": "4101760",
            "type": "article",
            "attributes": {
                "publishOn": "2017-08-24T17:49:55-04:00",
                "isLockedPro": false,
                "commentCount": 15,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson Is Doing Just Fine",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102459",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4101760-johnson-and-johnson-is-just-fine"
            }
        },
        {
            "id": "4101305",
            "type": "article",
            "attributes": {
                "publishOn": "2017-08-23T11:53:02-04:00",
                "isLockedPro": false,
                "commentCount": 46,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "The Top 5 Healthcare Dividend Stocks Today",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "63883",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4101305-top-5-healthcare-dividend-stocks-today"
            }
        },
        {
            "id": "4100942",
            "type": "article",
            "attributes": {
                "publishOn": "2017-08-22T10:21:27-04:00",
                "isLockedPro": false,
                "commentCount": 16,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: A Dividend Aristocrat You Must Neither Sell Nor Buy At These Prices",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103050",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4100942-johnson-and-johnson-dividend-aristocrat-you-must-neither-sell-buy-prices"
            }
        },
        {
            "id": "4100588",
            "type": "article",
            "attributes": {
                "publishOn": "2017-08-21T07:56:36-04:00",
                "isLockedPro": false,
                "commentCount": 33,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Bring On The Ambulance Chasers",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "87336",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4100588-johnson-and-johnson-bring-on-ambulance-chasers"
            }
        },
        {
            "id": "4100059",
            "type": "article",
            "attributes": {
                "publishOn": "2017-08-18T10:11:05-04:00",
                "isLockedPro": false,
                "commentCount": 174,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Sell Now",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102301",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4100059-johnson-and-johnson-sell-now"
            }
        },
        {
            "id": "4099087",
            "type": "article",
            "attributes": {
                "publishOn": "2017-08-15T12:55:33-04:00",
                "isLockedPro": false,
                "commentCount": 97,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "A 'Tidal Wave' Of Lawsuits Facing Johnson & Johnson Due To The Opioid Crisis",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23998",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4099087-tidal-wave-of-lawsuits-facing-johnson-and-johnson-due-to-opioid-crisis"
            }
        },
        {
            "id": "4099004",
            "type": "article",
            "attributes": {
                "publishOn": "2017-08-15T08:34:13-04:00",
                "isLockedPro": false,
                "commentCount": 10,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: After Rising 15% This Year, What's Next?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103394",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "191194",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4099004-johnson-and-johnson-after-rising-15-percent-this-year-next"
            }
        },
        {
            "id": "4095791",
            "type": "article",
            "attributes": {
                "publishOn": "2017-08-07T08:19:41-04:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson Receives Massive 'No' From Panel: Hope Left?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "58061",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "190794",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4095791-johnson-and-johnson-receives-massive-no-from-panel-hope-left"
            }
        },
        {
            "id": "4095172",
            "type": "article",
            "attributes": {
                "publishOn": "2017-08-04T17:41:49-04:00",
                "isLockedPro": false,
                "commentCount": 24,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Wait For The Drop Or Take The Shot?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "65113",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "190758",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4095172-johnson-and-johnson-wait-for-drop-take-shot"
            }
        },
        {
            "id": "4092490",
            "type": "article",
            "attributes": {
                "publishOn": "2017-07-30T14:48:09-04:00",
                "isLockedPro": false,
                "commentCount": 25,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Recent Dip Creates Opportunity For Dividend Growth Investors",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103321",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4092490-johnson-and-johnson-recent-dip-creates-opportunity-for-dividend-growth-investors"
            }
        },
        {
            "id": "4091288",
            "type": "article",
            "attributes": {
                "publishOn": "2017-07-27T11:37:16-04:00",
                "isLockedPro": false,
                "commentCount": 28,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson Takes Down Medtronic And AbbVie",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102428",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4091288-johnson-and-johnson-takes-down-medtronic-and-abbvie"
            }
        },
        {
            "id": "4091110",
            "type": "article",
            "attributes": {
                "publishOn": "2017-07-27T05:59:37-04:00",
                "isLockedPro": false,
                "commentCount": 34,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Now Is A Good Time To Buy Johnson & Johnson",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23468",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4091110-now-is-good-time-to-buy-johnson-and-johnson"
            }
        },
        {
            "id": "4089421",
            "type": "article",
            "attributes": {
                "publishOn": "2017-07-21T12:17:54-04:00",
                "isLockedPro": false,
                "commentCount": 17,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson Is A Defensive Stock And Should Be In All Portfolios, Income Or Growth",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "85096",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4089421-johnson-and-johnson-is-defensive-stock-and-should-be-in-all-portfolios-income-growth"
            }
        },
        {
            "id": "4088842",
            "type": "article",
            "attributes": {
                "publishOn": "2017-07-19T17:05:19-04:00",
                "isLockedPro": false,
                "commentCount": 13,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson's Weakness Worries Me",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "39011",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4088842-johnson-and-johnsons-weakness-worries-me"
            }
        },
        {
            "id": "4088799",
            "type": "article",
            "attributes": {
                "publishOn": "2017-07-19T15:01:18-04:00",
                "isLockedPro": false,
                "commentCount": 38,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: This Market Will Buy Anything",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "22148",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4088799-johnson-and-johnson-this-market-will-buy-anything"
            }
        },
        {
            "id": "4088736",
            "type": "article",
            "attributes": {
                "publishOn": "2017-07-19T12:56:56-04:00",
                "isLockedPro": false,
                "commentCount": 51,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "J&J: Some Good News, But Here's Why It's Dropped A Level Or Two",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "43041",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4088736-j-and-j-good-news-why-dropped-level-two"
            }
        },
        {
            "id": "4088468",
            "type": "article",
            "attributes": {
                "publishOn": "2017-07-18T13:52:22-04:00",
                "isLockedPro": false,
                "commentCount": 13,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson Is Delivering",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "33291",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "189958",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4088468-johnson-and-johnson-is-delivering"
            }
        },
        {
            "id": "4088387",
            "type": "article",
            "attributes": {
                "publishOn": "2017-07-18T09:34:38-04:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson's Tremfya: A Potential Blockbuster Drug",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103050",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4088387-johnson-and-johnsons-tremfya-potential-blockbuster-drug"
            }
        },
        {
            "id": "4088182",
            "type": "article",
            "attributes": {
                "publishOn": "2017-07-17T15:00:06-04:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Approval Of TREMFYA Is Huge Win For Shareholders",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "58061",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "189899",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4088182-johnson-and-johnson-approval-of-tremfya-is-huge-win-for-shareholders"
            }
        },
        {
            "id": "4087855",
            "type": "article",
            "attributes": {
                "publishOn": "2017-07-14T18:19:30-04:00",
                "isLockedPro": false,
                "commentCount": 17,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Previewing Johnson & Johnson Earnings",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "39011",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4087855-previewing-johnson-and-johnson-earnings"
            }
        },
        {
            "id": "4086627",
            "type": "article",
            "attributes": {
                "publishOn": "2017-07-10T10:48:00-04:00",
                "isLockedPro": false,
                "commentCount": 43,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Assessing The Talcum Powder Litigation Threat To Johnson & Johnson",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "68315",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4086627-assessing-talcum-powder-litigation-threat-to-johnson-and-johnson"
            }
        },
        {
            "id": "4085891",
            "type": "article",
            "attributes": {
                "publishOn": "2017-07-05T16:14:11-04:00",
                "isLockedPro": false,
                "commentCount": 7,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Where's The Growth Coming From?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "39011",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4085891-johnson-and-johnson-growth-coming-from"
            }
        },
        {
            "id": "4085870",
            "type": "article",
            "attributes": {
                "publishOn": "2017-07-05T14:38:35-04:00",
                "isLockedPro": false,
                "commentCount": 6,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Interview - Johnson & Johnson Breathes New Life Into Infectious Diseases",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "21877",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4085870-interview-johnson-and-johnson-breathes-new-life-infectious-diseases"
            }
        },
        {
            "id": "4085685",
            "type": "article",
            "attributes": {
                "publishOn": "2017-07-05T09:00:00-04:00",
                "isLockedPro": false,
                "commentCount": 391,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "If I Had To Buy One Stock Right Now",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24971",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4085685-i-to-buy-one-stock-right-now"
            }
        }
    ]
}